[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"6d7c8fa9-67d2-4bc9-bef1-9bdadb373194","acronym":"","url":"https://clinicaltrials.gov/study/NCT04863430","created_at":"2021-04-28T12:52:46.950Z","updated_at":"2025-02-25T13:49:08.094Z","phase":"Phase 2","brief_title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","source_id_and_acronym":"NCT04863430","lead_sponsor":"Peking University","biomarkers":" HER-2 • GPC3 • SALL4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • GPC3 • SALL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 07/06/2023","primary_completion_date":" 07/06/2023","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2025-02-21"},{"id":"b85874df-7e06-4405-a134-b832b090826f","acronym":"RCTS","url":"https://clinicaltrials.gov/study/NCT05586061","created_at":"2022-10-19T13:56:28.812Z","updated_at":"2025-02-25T16:33:09.486Z","phase":"Phase 2","brief_title":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","source_id_and_acronym":"NCT05586061 - RCTS","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/29/2024","primary_completion_date":" 12/29/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"cd1a66a4-5dbf-4a32-901c-c7c94f2f942d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06576921","created_at":"2025-02-26T06:54:16.281Z","updated_at":"2025-02-26T06:54:16.281Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","source_id_and_acronym":"NCT06576921","lead_sponsor":"Xijing Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • oxaliplatin • Hetronifly (serplulimab) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-01-13"},{"id":"eac09468-ac4c-46bb-959d-a841edea238a","acronym":"KEYNOTE-659","url":"https://clinicaltrials.gov/study/NCT03382600","created_at":"2021-01-17T17:22:20.283Z","updated_at":"2024-07-02T16:34:27.517Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)","source_id_and_acronym":"NCT03382600 - KEYNOTE-659","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 05/30/2021","primary_completion_date":" 05/30/2021","study_txt":" Completion: 05/30/2021","study_completion_date":" 05/30/2021","last_update_posted":"2024-06-11"},{"id":"b40384af-5c68-46d2-897b-8d188207306f","acronym":"KEYNOTE 811","url":"https://clinicaltrials.gov/study/NCT03615326","created_at":"2021-01-18T17:46:00.243Z","updated_at":"2024-07-02T16:35:09.730Z","phase":"Phase 3","brief_title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","source_id_and_acronym":"NCT03615326 - KEYNOTE 811","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 738","initiation":"Initiation: 10/05/2018","start_date":" 10/05/2018","primary_txt":" Primary completion: 03/20/2024","primary_completion_date":" 03/20/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-15"},{"id":"adb47411-e4ca-44c0-af22-a98798c3a97a","acronym":"EC-CRT-007","url":"https://clinicaltrials.gov/study/NCT06187597","created_at":"2024-01-02T14:16:57.201Z","updated_at":"2024-07-02T16:35:15.221Z","phase":"Phase 2","brief_title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","source_id_and_acronym":"NCT06187597 - EC-CRT-007","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40","pipe":"","alterations":" ","tags":["IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-12"},{"id":"b1dc5803-3a3c-484f-a5f9-c84389621cfd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04694183","created_at":"2021-01-19T20:49:14.341Z","updated_at":"2024-07-02T16:35:20.387Z","phase":"Phase 2","brief_title":"The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer","source_id_and_acronym":"NCT04694183","lead_sponsor":"Quan Wang","biomarkers":" HER-2 • PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative","tags":["HER-2 • PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiRuiKa (camrelizumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/17/2020","start_date":" 08/17/2020","primary_txt":" Primary completion: 05/06/2023","primary_completion_date":" 05/06/2023","study_txt":" Completion: 05/06/2023","study_completion_date":" 05/06/2023","last_update_posted":"2024-02-07"},{"id":"c3b5e701-e66f-42af-8315-cc08cb5dd2ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05403242","created_at":"2022-06-03T12:55:12.504Z","updated_at":"2024-07-02T16:35:24.297Z","phase":"Phase 1/2","brief_title":"RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2","source_id_and_acronym":"NCT05403242","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-01-08"},{"id":"1bab45f4-b237-43ea-9129-747fc43e0430","acronym":"","url":"https://clinicaltrials.gov/study/NCT04221555","created_at":"2021-01-18T20:32:52.568Z","updated_at":"2024-07-02T16:35:24.920Z","phase":"Phase 2","brief_title":"Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT04221555","lead_sponsor":"Asan Medical Center","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Imjudo (tremelimumab-actl) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 05/13/2020","start_date":" 05/13/2020","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-12-29"},{"id":"31256609-b0dc-4eb1-ada7-4e2a7dbb2e09","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046963","created_at":"2023-09-21T14:10:30.233Z","updated_at":"2024-07-02T16:35:36.521Z","phase":"Phase 2","brief_title":"Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites","source_id_and_acronym":"NCT06046963","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-21"},{"id":"271e7fdf-8d02-4873-b54f-f0cc79e784c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03406299","created_at":"2021-01-18T14:26:32.423Z","updated_at":"2024-07-02T16:35:50.949Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT03406299","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" CDKN2A • ARID1A • IL6 • HGF • CXCL1 • CXCL3","pipe":"","alterations":" ","tags":["CDKN2A • ARID1A • IL6 • HGF • CXCL1 • CXCL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-04-11"},{"id":"641b80c3-a80d-4b84-9d36-9c8f22ebf413","acronym":"","url":"https://clinicaltrials.gov/study/NCT04047953","created_at":"2021-01-18T19:51:13.817Z","updated_at":"2024-07-02T16:35:51.397Z","phase":"","brief_title":"Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma","source_id_and_acronym":"NCT04047953","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 09/10/2019","start_date":" 09/10/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-04-05"},{"id":"cd56cf4d-3c31-4526-adbd-cc60f37646ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT05774964","created_at":"2023-03-20T20:03:21.979Z","updated_at":"2024-07-02T16:35:52.913Z","phase":"Phase 2","brief_title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","source_id_and_acronym":"NCT05774964","lead_sponsor":"Liaoning Tumor Hospital \u0026 Institute","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF mutation • KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 03/15/2025","study_completion_date":" 03/15/2025","last_update_posted":"2023-03-20"},{"id":"40e0b032-116e-47aa-8c4a-24a6a09143af","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769725","created_at":"2023-03-15T14:02:25.080Z","updated_at":"2024-07-02T16:35:53.234Z","phase":"Phase 2","brief_title":"A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer","source_id_and_acronym":"NCT05769725","lead_sponsor":"RenJi Hospital","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Hetronifly (serplulimab) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-03-15"},{"id":"afed1d96-67f1-4652-9aef-c45127a16553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627414","created_at":"2022-11-25T15:58:18.406Z","updated_at":"2024-07-02T16:35:59.966Z","phase":"Phase 2","brief_title":"Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer","source_id_and_acronym":"NCT05627414","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tyvyt (sintilimab) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2022-11-24"},{"id":"399b9815-41d3-46eb-8c6a-e4e1e7e9df5e","acronym":"NICE","url":"https://clinicaltrials.gov/study/NCT04744649","created_at":"2021-02-09T14:53:05.598Z","updated_at":"2024-07-02T16:36:00.412Z","phase":"Phase 2","brief_title":"Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial","source_id_and_acronym":"NCT04744649 - NICE","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 03/12/2021","start_date":" 03/12/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-15"},{"id":"9ac9f050-2f2a-4b3c-aad8-e95ba903e1a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05528367","created_at":"2022-09-06T17:03:09.968Z","updated_at":"2024-07-02T16:36:04.474Z","phase":"Phase 2","brief_title":"Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT05528367","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-09-05"},{"id":"49294c43-a559-4ab4-a316-65f83f03b8af","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02725424","created_at":"2021-01-18T13:20:20.673Z","updated_at":"2024-07-02T16:36:05.329Z","phase":"Phase 2","brief_title":"Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer","source_id_and_acronym":"NCT02725424 - NCI-MATCH","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2022-08-17"},{"id":"9653dfea-b314-42ba-85bf-254d9e1c24d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415853","created_at":"2021-01-18T21:17:00.808Z","updated_at":"2024-07-02T16:36:05.477Z","phase":"Phase 3","brief_title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","source_id_and_acronym":"NCT04415853","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Teysuno (gimeracil/oteracil/tegafur) • larotinib (Z650)"],"overall_status":"Recruiting","enrollment":" Enrollment 416","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2022-08-15"},{"id":"edfa5958-650a-48b7-9dfd-281f7088e221","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441254","created_at":"2022-07-01T21:55:32.005Z","updated_at":"2024-07-02T16:36:07.610Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study","source_id_and_acronym":"NCT05441254","lead_sponsor":"Zhongshan Hospital Xiamen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-07-08"},{"id":"78873f05-dd17-42fb-a929-a1c80e529357","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410847","created_at":"2022-06-08T11:58:17.482Z","updated_at":"2024-07-02T16:36:08.308Z","phase":"Phase 2","brief_title":"Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells","source_id_and_acronym":"NCT05410847","lead_sponsor":"Hebei Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-06-24"},{"id":"f0bd337c-4452-4371-babc-f6955210249b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04675866","created_at":"2021-01-19T20:45:14.300Z","updated_at":"2024-07-02T16:36:12.372Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer","source_id_and_acronym":"NCT04675866","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 08/17/2020","start_date":" 08/17/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-04-15"}]